News

September 29, 2022

Ember burns bright for Angle

A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.

September 29, 2022

CTAD 2022 preview – looking beyond lecanemab

September 23, 2022

Ferring gets a yes, but a Seres threat is looming

September 22, 2022

Novartis starts the fight back

September 21, 2022

Satsuma’s second chance nears readout

September 20, 2022

More hard knocks for the blank cheque space

September 16, 2022

Intellia delivers a second knockdown success

Encouraging early results in hereditary angioedema join further progress in amyloidosis, but investors remain wary.

September 16, 2022

Astrazeneca pulls ahead in haemoglobinuria

September 16, 2022

Third Harmonic shows flotations can happen

September 15, 2022

Pfizer reads out first in another GSK vaccine duel

September 14, 2022

Altimmune posts a metabolic let-down

Load More